[CH:1]([NH:4][C:5]1[C:6]([N:11]2[CH2:16][CH2:15][N:14]([C:17]([C:19]3[CH:32]=[CH:31][C:22]([C:23]([N:25]4[CH2:30][CH2:29][NH:28][CH2:27][CH2:26]4)=[O:24])=[CH:21][CH:20]=3)=[O:18])[CH2:13][CH2:12]2)=[N:7][CH:8]=[CH:9][CH:10]=1)([CH3:3])[CH3:2].CN1CCOCC1.[CH:40]1(Br)[CH2:44][CH2:43][CH2:42][CH2:41]1>C(#N)C>[CH:40]1([N:28]2[CH2:27][CH2:26][N:25]([C:23](=[O:24])[C:22]3[CH:21]=[CH:20][C:19]([C:17]([N:14]4[CH2:15][CH2:16][N:11]([C:6]5[C:5]([NH:4][CH:1]([CH3:3])[CH3:2])=[CH:10][CH:9]=[CH:8][N:7]=5)[CH2:12][CH2:13]4)=[O:18])=[CH:32][CH:31]=3)[CH2:30][CH2:29]2)[CH2:44][CH2:43][CH2:42][CH2:41]11-[4-[1-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine (0.5 g) was dissolved in acetonitrile (25 ml) and then, N-methylmorpholine (0.17 ml) and cyclopentyl bromide (0.3 ml) were added. The solution was heated to 65~75° C. and stirred for 20 hours. The solvent was concentrated under reduced pressure and then, the residue was dissolved in chloroform (40 ml). The solution was washed with water twice and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether and hexane, and further recrystallized using ethanol and isopropyl ether. The recrystallized product was filtered and dried to give 0.41 g (yield: 71%) of the desired compound.